Investigation of 118 patients for protein C deficiency using an immunological and a functional assay, and subsequent investigation of those (nine) found to be deficient, identified 22 patients (14 women, eight men) with protein C deficiency, of whom six were asymptomatic, 15 had histories of venous thromboembolism, and one had a history of arterial thromboembolism. Protein C deficiency was associated in the nine probands with young age at first episode of thromboembolic disease (mean 24-1 (SD 11-9) years), absence of a precipitating condition (five (56%)), and a family history of thromboembolic disease (six (66%)). Investigation of the nine families suggested autosomal dominant transmission of the defect.
Introduction
Recent descriptions of families with thrombotic disease and isolated protein C deficiency'-6 have confirmed biochemical findings on the anticoagulant properties of protein C recently reviewed by Esmon.7 Protein C, a vitamin K dependent plasma zymogen synthesised in the liver, is activated by thrombin ( fig 1) ; thrombomodulin, a protein present on the endothelial cell surface, acts as a cofactor in this reaction. Regulation of protein C activation is also dependent on protein S, another vitamin K dependent plasma protein, and on a specific inhibitor. Activated protein C functions as an anticoagulant by inactivating factors Va and VIIIa and, possibly, by stimulating fibrinolysis.
Thrombotic disease is associated with protein C deficiency as the impaired inactivation of factors Va and VIIIa promotes excessive formation of fibrin. We investigated 118 patients with documented venous thromboembolic disease for the presence of isolated protein C deficiency, using both a functional and an immunological assay for protein C.
Laboratoire Central d'Hematologie, Hotel-Dieu, 75181 Other variables of coagulation, such as prothrombin time, partial thromboplastin time, thrombin time, fibrinogen activity, euglobulin clot lysis time, and diluted whole blood lysis time, were measured as described by Caen et al. 10 Euglobulin lysis time and diluted whole blood lysis time were measured both before and after 10 minutes' venous occlusion. Plasminogen and antithrombin III activity were assayed with specific amidolytic methods using the substrates S-225 1 and S-2238 respectively.
Results
Of the 118 patients studied (117 with venous thrombosis, one with arterial thrombosis), nine (7 6%) were found to have isolated protein C deficiency. Further studies of their families permitted the identification of a further 13 patients with isolated protein C deficiency (fig 2) . congenital protein C deficiency, submitted for publication). Of the 22 patients with isolated protein C deficiency, 21 were found to be heterozygous for the defect. Only one patient (case 14) showed a low protein C antigen concentration and protein C activity, with the concentrations of the other vitamin K dependent factors within the normal range. Both his parents (cases 15 and 16)-who were cousins-had isolated protein C deficiency. This patient (case 14) might have been either a homozygote with a mild defect or a heterozygote with an extremely low protein C activity.
Protein C activity could be determined in only 33 of 64 patients who did not receive oral anticoagulant treatment, so decreased functional activity (molecular variant) could not be excluded in 31 patients with thrombotic disease who had normal protein C antigen concentrations.
Discussion
Clinical manifestations of venou-s thromboembolism in 15 patients out of 22 with isolated protein C deficiency confirmed the previously described association between thromboembolic disease and isolated protein C deficiency. Relatively young age at the first episode of thrombosis, absence of precipitating factors, and familial history of deep vein thrombosis characterised the nine probands with protein C deficiency in a large population of patients with thromboembolic disease. Protein C deficiency was detected in eight (7 6%) of the patients with a first episode before 40 years and in five (7%) of the patients with recurrent thromboembolic episodes. Protein C deficiency seems to be more common than antithrombin III deficiency, which has been detected in 4-4% of patients with recurrent venous thrombosis.'2 Pabinger-Fasching et al observed a higher incidence (2-3%) of antithrombin III deficiency compared with protein C deficiency (1%). The lower average age of our patients may explain this discrepancy:
Broekmans et al observed an incidence of 8-1% in patients younger than 40, compared with 1 2% in patients over 40.
As previously described, a protein C antigen concentration lower than 0-6 U/ml is associated with a history of deep vein thrombosis. Not all our patients with protein C activity lower than 0-6 U/ml, however, had experienced thromboembolic episodes. In addition, we identified one who might have been homozygous for a mild deficiency. Homozygotes with a severe deficiency (plasma protein C antigen activity less than 0 05 U/ml) have been reported: all were newborn infants with diffuse thromboses'3 or purpura fulminans.' 4 Broekmans et al proposed that protein C deficiency is transmitted as an autosomal dominant disorder.2 A recessive autosomal transmission has, however, been suggested by Seligsohn et al. 13 Autosomal dominant transmission was confirmed in seven out of the nine families assessed: transmission from mother to daughter was found in five families, from father to daughter in one, from father to son in one. One patient (case 1 1) with severe protein C deficiency whose parents were both heterozygous might have been a heterozygote with an extremely low protein C activity or a homozygote for a mild defect.
Choice and duration of the antithrombotic treatment in protein C deficiency continue to be discussed: heparin has been observed to be effective in the acute phase ofdeep vein thrombosis. Introduction of oral anticoagulation may be associated with skin necrosis in patients with protein C deficiency, as recently described '5 16: only one of our patients (case 11, with severe protein C deficiency) showed recurrent skin necrosis at the introduction of oral anticoagulation. 16 Thirteen others were treated on several occasions without any complications. If protein C deficiency is suspected the introduction of oral anticoagulant treatment must be progressive and associated with intensive heparin anticoagulation to prevent thrombosis of the microcirculation occurring with low protein C activities.
Long term treatment with an oral anticoagulant drug seems to be beneficial in preventing recurrences of venous thromboembolism in patients with protein C deficiency: of our patients who did not receive anticoagulant treatment, seven had recurrent deep vein thrombosis and five recurrent superficial thrombophlebitis. Fifteen of the 22 patients with protein C deficiency, however, did not receive oral anticoagulant treatment. Longer follow up is necessary to make a definite statement on the prevention of recurrence by long term treatment with oral anticoagulant.
Protein C deficiency seems to be one of the most commonly observed inherited abnormalities of coagulation predisposing to thrombosis (roughly 7% incidence in our series), others being quantitative or qualitative alterations in antithrombin III, plasminogen, and fibrinogen activities. Thus evaluation of protein C activity is of interest in patients with thromboembolic disease, particularly in young patients without precipitating conditions of the thromboembolic episode or with a familial history of thromboembolism, or with both. Lurking behind this question is the fear that giving corticosteroids to a patient with a peptic ulcer will cause that ulcer to perforate or bleed or, at least, will prevent it healing. Though widespread, this fear is not soundly based. The evidence that corticosteroids induce peptic ulcer is conflicting and unconvincing,' and there is no better evidence that steroids worsen the course of the disease. I would recommend that the patient should be given prednisolone in the normal way and also that cimetidine or ranitidine are given in full dosage for four weeks, when endoscopy is advisable to discover if the ulcer has healed. If it has the dose of the H2-blocking drug may be reduced to 400 mg cimetidine or 150 mg ranitidine at bedtime. To be on the safe side, this dose should be continued until the corticosteroid drug has been tailed off. If the ulcer has not healed at four weeks or if symptoms persist after the first few days of H2-blocking treatment I would recommend adding a locally active drug such as sucralfate or dicitratopotassium bismuthate (De-Nol).-K W HEATON, reader in medicine, Bristol. Are asbestos fire blankets effective and are they hazardous when coming into contact with fires?
Asbestos fibre blankets are effective, but nowadays "fire blankets" (made from non-asbestos textiles) may be used. When asbestos fire blankets are pulled out of a container and shaken some asbestos fibres are released into the atmosphere but disperse quite soon. There is, therefore, a theoretical risk from the asbestos, but it must be infinitesimal compared with that from the fire.-w R LEE, professor of occupational health, Manchester.
